{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:04:37Z","timestamp":1783065877194,"version":"3.54.6"},"reference-count":33,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Excessive aldosterone secretion causes a high risk of cardio-cerebrovascular events. Mineralocorticoid receptor antagonist (MRA) is 1 of the treatment strategies for primary aldosteronism (PA). However, current MRA treatment is insufficient because MRA-treated patients with suppressed plasma renin activity (PRA)\u2005&amp;lt;\u20051 ng\/mL\/h still had a higher risk of cardiovascular disease than those with unsuppressed PRA. This is a prospective interventional study to determine the effects of an increase in MRA dosage on blood pressure (BP) control and urinary albumin excretion (UAE) in MRA-treated PA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Thirty-four PA patients were recruited, and 24 patients (6 male, 18 female) completed this study. Serum potassium concentration was assessed every two months to adjust the dosage of MRA safely for 6 months. The primary outcomes were the changes in BP and UAE between baseline and 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Systolic BP (SBP) and log10UAE decreased significantly as the daily dose of MRA increased. Diastolic BP (DBP) tended to decrease. We divided the PA patients into two groups (baseline PRA\u2005&amp;lt;\u20051 ng\/mL\/h and baseline PRA\u2005\u2265\u20051 ng\/mL\/h) according to PRA. In the group with baseline PRA\u2005&amp;lt;\u20051 ng\/mL\/h but not that with baseline PRA\u2005\u2265\u20051 ng\/mL\/h, SBP, DBP and log10UAE after 6 months were significantly lower than those at baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The increase in MRA dosage improved BP and UAE in PA patients with suppressed PRA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvab174","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T04:37:00Z","timestamp":1639197420000},"source":"Crossref","is-referenced-by-count":25,"title":["Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin"],"prefix":"10.1210","volume":"6","author":[{"given":"Aya","family":"Saiki","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-8621","authenticated-orcid":false,"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4614-9137","authenticated-orcid":false,"given":"Tetsuhiro","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-5561","authenticated-orcid":false,"given":"Kosuke","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-9315","authenticated-orcid":false,"given":"Koichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"issue":"9","key":"2021121103152326600_CIT0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism\u2013the Japan Endocrine Society 2009","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr J."},{"issue":"5","key":"2021121103152326600_CIT0002","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021121103152326600_CIT0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2021121103152326600_CIT0004","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest."},{"issue":"1","key":"2021121103152326600_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int."},{"issue":"2","key":"2021121103152326600_CIT0006","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension."},{"issue":"1","key":"2021121103152326600_CIT0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med."},{"issue":"22","key":"2021121103152326600_CIT0008","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA."},{"issue":"4","key":"2021121103152326600_CIT0009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"2021121103152326600_CIT0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertens Res."},{"issue":"9","key":"2021121103152326600_CIT0011","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021121103152326600_CIT0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2021121103152326600_CIT0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/hr.2014.20","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)","volume":"37","author":"Shimamoto","year":"2014","journal-title":"Hypertens Res."},{"issue":"11","key":"2021121103152326600_CIT0014","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"2021121103152326600_CIT0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0895-4356(98)00096-1","article-title":"Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol."},{"key":"2021121103152326600_CIT0016"},{"key":"2021121103152326600_CIT0017"},{"issue":"5","key":"2021121103152326600_CIT0018","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"2021121103152326600_CIT0019","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/jc.2008-2245","article-title":"Intrarenal hemodynamics in primary aldosteronism before and after treatment","volume":"94","author":"Sechi","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121103152326600_CIT0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension."},{"issue":"3","key":"2021121103152326600_CIT0021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ajh.2008.356","article-title":"Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC study","volume":"22","author":"Ikeda","year":"2009","journal-title":"Am J Hypertens."},{"issue":"4","key":"2021121103152326600_CIT0022","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41440-018-0123-4","article-title":"Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis","volume":"42","author":"Sakima","year":"2019","journal-title":"Hypertens Res."},{"issue":"1","key":"2021121103152326600_CIT0023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstr\u00f6m","year":"2018","journal-title":"JAMA Intern Med."},{"issue":"9","key":"2021121103152326600_CIT0024","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/HJH.0000000000000991","article-title":"Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis","volume":"34","author":"Viazzi","year":"2016","journal-title":"J Hypertens."},{"issue":"5","key":"2021121103152326600_CIT0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"2021121103152326600_CIT0026","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension."},{"issue":"3","key":"2021121103152326600_CIT0027","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021121103152326600_CIT0028","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0040270","article-title":"Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review","volume":"4","author":"Di Angelantonio","year":"2007","journal-title":"PloS Med."},{"issue":"10","key":"2021121103152326600_CIT0029","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1371\/journal.pmed.0050207","article-title":"The relationship between proteinuria and coronary risk: a systematic review and meta-analysis","volume":"5","author":"Perkovic","year":"2008","journal-title":"PloS Med."},{"issue":"9731","key":"2021121103152326600_CIT0030","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"2021121103152326600_CIT0031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41440-018-0116-3","article-title":"Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Mishima","year":"2019","journal-title":"Hypertens Res."},{"issue":"8","key":"2021121103152326600_CIT0032","doi-asserted-by":"crossref","first-page":"716","DOI":"10.21037\/atm-20-4841","article-title":"A narrative review of new treatment options for chronic kidney disease in type 2 diabetes","volume":"9","author":"Persson","year":"2021","journal-title":"Ann Transl Med."},{"issue":"9","key":"2021121103152326600_CIT0033","doi-asserted-by":"crossref","first-page":"e3655","DOI":"10.1210\/clinem\/dgab290","article-title":"Mineralocorticoid receptor antagonist effect on aldosterone to renin ratio in patients with primary aldosteronism","volume":"106","author":"Pecori","year":"2021","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/1\/bvab174\/41722660\/bvab174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/6\/1\/bvab174\/41722660\/bvab174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T04:37:22Z","timestamp":1639197442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvab174\/6432231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvab174","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,11,19]]},"article-number":"bvab174"}}